Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2015-04-28 Regulatory Filings
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2015
Regulatory Filings
2015-04-28 English
Regulatory Filings 2015
Regulatory Filings Classification · 100% confidence The document is a letter from Novavax, Inc. responding to comments from the SEC staff regarding their Preliminary Proxy Statement on Schedule 14A. The content focuses on amendments to the certificate of incorporation related to authorized shares and disclosures about share issuance plans. It is not the proxy statement itself but a correspondence addressing SEC comments on that filing. The document length is short (3148 characters) and it is clearly a regulatory correspondence related to a proxy statement, not the proxy statement or definitive filing itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such SEC comment letters and responses that do not constitute the actual report or filing.
2015-04-28 English
Regulatory Filings 2015
Regulatory Filings
2015-04-24 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, which is used to solicit shareholder votes for an upcoming Annual Meeting. It includes detailed information about the meeting agenda, voting procedures, and corporate governance matters. It references the Annual Meeting date, proposals to be voted on, and includes proxy voting instructions. It also mentions the availability of the Annual Report but does not contain the report itself. The document is not a full Annual Report (10-K), Earnings Release, or other financial report but is clearly a Proxy Solicitation document. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length and content support a high confidence level.
2015-04-20 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 25, 2015, by Novavax, Inc. It reports the entry into a material definitive agreement, specifically an underwriting agreement related to a public offering of common stock. The document includes details about the offering, the underwriting agreement, and related press releases. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The primary content is an update on a financing transaction. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). The document length is 4823 characters, which is sufficient to contain substantive information about the financing event itself, not just an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2015-03-27 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details a public offering of common stock by Novavax, Inc., including the number of shares, pricing, underwriting discounts, and use of proceeds. The document includes a prospectus supplement and accompanying prospectus with detailed information about the company, its business, risk factors, and the offering terms. This type of filing is a capital raising document related to a securities offering, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or a brief summary.
2015-03-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.